ARV Facts

Facts about Antiretroviral Drugs

Arrow to the left Back to the Homepage

Active substance: Atazanavir
Manufacturer: Bristol-Myers Squibb (UK)

Extract from the prescribing information:

"Patients should be informed that REYATAZ is not a cure for HIV infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease. Patients should be told that there are currently no data demonstrating that therapy with REYATAZ can reduce the risk of transmitting HIV to others through sexual contact."

Known side effects: more immune deficiency

“Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions (including, but not limited to, severe rash or rash accompanied by one or more of the following: fever, general malaise, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, granulocytopenia, lymphadenopathy, and renal dysfunction) must discontinue REYATAZ and seek medical evaluation immediately.”

Granulocytopenia = Low levels of granulocytes – a subtype of white blood cells (leucocytes) responsible for immune defence against infections – due to toxic effects of ARVs on blood cell formation in the bone marrow

The above has been extracted from the Reyataz prescribing information on the Bristol-Myers Squibb webpages.